InsidersTradesSigma
Track the Intellia Therapeutics, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Intellia Therapeutics, Inc. has published 165 insider filings. Market capitalisation: €1.8bn. The latest transaction was disclosed on 24 August 2026 (Cession). Among the most active insiders: LEONARD JOHN M. The full history is free.
165
Insider Decl.
n/a
Thresholds
€2m
2 ops.
Buy Volume
€9m
51 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Intellia Therapeutics, Inc. Buy (bullish), based on 17 analysts. Average price target: US$23.94.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations165 total
19,890 shares@ US$12.60Common StockSEC:0001193125-26-363567:0
2,785 shares@ US$13.00Common StockSEC:0001193125-26-363567:1
22,675 shares@ US$12.950.018% mcap9.7% of flowCommonSEC144:0001969223-26-000938
8,111 shares@ US$11.250.0059% mcap27.3% of flowCommon StockSEC:0001193125-26-316279:0
2,641 shares@ US$16.780.0028% mcap43.4% of flowCommon StockSEC:0002019493-26-000002:0
4,677 shares@ US$18.000.0053% mcap100.0% of flowCommon StockSEC:0001821530-26-000002:0
4,677 shares@ US$17.240.0051% mcap100.0% of flowCOMMONSEC144:0001950047-26-006836
9,200 sharesCommon StockSEC:0001193125-26-266236:0
9,200 sharesCommon StockSEC:0001193125-26-266230:0
9,200 sharesCommon StockSEC:0001563572-26-000001:0
9,200 sharesCommon StockSEC:0001193125-26-266233:0
9,200 sharesCommon StockSEC:0001756929-26-000002:0
156,400 shares0Common StockSEC:0001193125-26-088269:0
46,080 shares0Common StockSEC:0001193125-26-088260:0
9,943 shares0Common StockSEC:0001193125-26-088258:0
61,280 shares0Common StockSEC:0001193125-26-088254:0
39,200 shares0Common StockSEC:0001193125-26-088251:0
7,353 shares0Common StockSEC:0001193125-26-088241:0
17,250 shares0Common StockSEC:0001193125-26-088236:0
34,146 shares@ US$9.2111.5% of flowCommon StockSEC:0001193125-26-006294:0
8,508 shares@ US$9.2199.3% of flowCommon StockSEC:0001193125-26-006292:0
10,397 shares@ US$9.2126.5% of flowCommon StockSEC:0001193125-26-006291:0
150,000 shares@ US$9.35100.0% of flowCommon StockSEC:0001193125-26-006288:0
Canonical exit: 5 Apr 2026 (T+90)
11,903 shares@ US$9.2114.0% of flowCommon StockSEC:0001193125-26-006283:0
9,515 shares@ US$9.2141.2% of flowCommon StockSEC:0001193125-26-006278:0
25 of 165 declarations
关于 Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. 是一家总部位于美国马萨诸塞州剑桥的生物技术公司，在纳斯达克上市，股票代码为NTLA。Intellia成立于2014年，已成为下一代基因编辑领域最受关注的公司之一，尤其是在体内CRISPR基因疗法方面。对于国际投资者而言，它符合典型的临床阶段生物技术公司特征：研发投入巨大，尚未产生可观的商业收入，其估值主要由临床执行、监管里程碑及其平台的长期前景驱动。（[ir.intelliatx.com](https://ir.intelliatx.com/?utm_source=openai)） Intellia的核心业务是开发旨在直接在体内编辑DNA的一次性疗法。该公司针对医疗需求未得到满足的严重疾病，特别是肝脏相关疾病、罕见遗传病以及通过持久干预可替代慢性疗法的特定适应症。Intellia强调其CRISPR能力和相关使能技术，以构建可能具有根本不同经济模式（与重复给药药物相比）的长期疗法。其产品组合目前主要集中于两个旗舰项目：用于转甲状腺素蛋白淀粉样变性的nexiguran ziclumeran (nex-z，前身为NTLA-2001)，以及用于遗传性血管性水肿的lonvoguran ziclumeran (lonvo-z，前身为NTLA-2002)。（[ir.intelliatx.com](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-8?utm_source=openai)） 从竞争角度来看，Intellia在以CRISPR为重点的生物技术公司中处于领先地位，与其它基因编辑专业公司并驾齐驱。其相对优势包括强大的科学特许经营权、对体内编辑的明确关注以及将项目推进到后期临床开发阶段的能力。与此同时，投资案例仍然具有固有的高风险：价值创造取决于试验结果、监管批准以及公司扩展工业和商业模式的能力，而该模式目前仍处于收入前阶段。（[ir.intelliatx.com](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-8?utm_source=openai)） 近期发展尤为重要。2026年3月，FDA解除了对nex-z治疗ATTR-CM的3期临床试验MAGNITUDE的临床搁置。2026年4月，Intellia公布了lonvo-z治疗遗传性血管性水肿的3期积极顶线数据，启动了向FDA滚动提交BLA的申请，并宣布了公开发行股票。这些事件标志着公司进入了一个关键时期，近期将迎来重大的监管和资本市场催化剂。（[ir.intelliatx.com](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-lift-clinical-hold-0?utm_source=openai)） 简而言之，Intellia Therapeutics是一家高风险、高回报的成长型生物技术公司，拥有差异化的CRISPR技术、处于后期阶段的管线以及在美国纳斯达克市场具有重要意义的近期催化剂。
